Company profile for ReviR Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ReviR Therapeutics is a research and development company aiming to treat human diseases by harnessing advanced AI technologies and RNA biology. Our AI-based platform allows us to explore beyond the protein-based target space to reach a large number of known disease targets previously considered "undruggable". Invent and build technologies to unlock first-in-class medicines for the treatment of cancer, rare genetic disorders, a...
ReviR Therapeutics is a research and development company aiming to treat human diseases by harnessing advanced AI technologies and RNA biology. Our AI-based platform allows us to explore beyond the protein-based target space to reach a large number of known disease targets previously considered "undruggable". Invent and build technologies to unlock first-in-class medicines for the treatment of cancer, rare genetic disorders, and infectious diseases * Decipher disease relevant structural and functional RNA motifs by integrating human genetic data, functional genomics, and AI

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
600 Gateway Blvd, 100A, South San Francisco, California 94080
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/revir-therapeutics-receives-4-6-million-cirm-grant-to-advance-huntingtons-disease-treatment-and-announces-key-development-milestone-302621485.html

PR NEWSWIRE
20 Nov 2025

https://www.prnewswire.com/news-releases/revir-therapeutics-receives-orphan-drug-designation-from-fda-for-rtx-117-to-treat-charcot-marie-tooth-disease-302581596.html

PR NEWSWIRE
13 Oct 2025

https://www.prnewswire.com/news-releases/revir-therapeutics-and-kennedys-disease-association-partner-to-advance-treatment-for-rare-neuromuscular-disorder-302315214.html

PR NEWSWIRE
25 Nov 2024

https://www.prnewswire.com/news-releases/revir-therapeutics-raises-30-million-series-a-financing-to-advance-its-proprietary-oral-genetic-medicines-for-multiple-cns-disorders-302206560.html

PR NEWSWIRE
26 Jul 2024

https://www.pharmabiz.com/NewsDetails.aspx?aid=169877&sid=2

PHARMABIZ
21 Jun 2024

https://www.prnewswire.com/news-releases/revir-therapeutics-reaches-milestone-in-novel-splicing-therapy-development-in-collaboration-with-asieris-pharmaceuticals-302171821.html

PR NEWSWIRE
17 Jun 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty